United Kingdom – England, Northern Ireland, Scotland & Wales

/United Kingdom - England, Northern Ireland, Scotland & Wales

United Kingdom

NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, is well tolerated, and improves survival.  After their review they have determined that Xtandi is an appropriate use of NHS resources, with an incremental cost-effectiveness ration of £34,500 compared to best supportive care. On the other hand NICE was less impressed with Johnson & Johnson's [...]

An Outrage in Leeds England – Prostate Cancer Survivor First Misdiagnosed & Then Stuck With £1,400 Bill For Chemotherapy

A story written by Dominic Horsley and published in the Yorkshire Evening Post claims that in May a 41 year old prostate cancer survivor from Woodlesford was referred to specialists at Leeds St James’s Hospital. He claimed that he had aches in his lower body but says t consultants told him that he was told he was “too young” to have prostate cancer. The making this determination the specialists didn’t consider that his father had already been diagnosed with prostate cancer. When he went to the Hospital he was told that he had prostatitis, an infection of the prostate. Despite [...]

Olaparib – Effective for Certain Genetic Metastatic Prostate Cancer Strains

I have talked a lot about our need to take the next step in clinical care, understanding the best sequencing of our drugs. Since we have a number of new drugs to treat advanced prostate cancer we now need to better understand which drugs should be used in which men as well as their proper sequencing. To do this we need to understand the genetic differences that our cancers have from each other. Cancer is a genetic disease and what we refer to, as prostate cancer is not one distinct disease, but it is many different diseases. To better sequence [...]

About the Important Genetic Prostate Cancer Study (UKGPCS) in the United Kingdom

Cancer is a genetic disease, so prostate cancer is a genetic problem. This statement might be the most important one we can make when trying to describe the current, overall situation we face as prostate cancer survivors! Many institutions have begun significant research studies trying to understand the actual genetic keys to prostate cancer. Prostate cancer risk, prostate cancer progression and prostate cancer treatments are all affected by genetics. What could be both the largest and longest running study of prostate cancer genetics has been going on in the United Kingdom (UK) since 1993. It involves 189 hospitals through out [...]